Immutep To Present New Data From EFTISARC-NEO Phase II Evaluating Novel Triple Combination Including Efti In Soft Tissue Sarcoma
Portfolio Pulse from Benzinga Newsdesk
Immutep Limited will present new data from its Phase II trial, EFTISARC-NEO, at the CTOS 2024 Annual Meeting. The trial evaluates a novel triple combination therapy for soft tissue sarcoma, involving eftilagimod alpha, radiotherapy, and KEYTRUDA®.
September 18, 2024 | 12:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Immutep Limited is set to present promising new data from its EFTISARC-NEO Phase II trial at the CTOS 2024 Annual Meeting. This trial explores a novel triple combination therapy for soft tissue sarcoma, a challenging orphan disease. The presentation could enhance Immutep's visibility and credibility in the oncology field.
The announcement of new data from a Phase II trial at a major oncology meeting is significant for Immutep. It highlights the company's progress in developing a novel treatment for a difficult-to-treat cancer, which could lead to increased interest and investment in the company. The presentation at CTOS 2024 provides a platform for Immutep to showcase its research to a specialized audience, potentially leading to partnerships or further clinical developments.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90